JPH02202A - 徐放性医薬製剤 - Google Patents
徐放性医薬製剤Info
- Publication number
- JPH02202A JPH02202A JP63321856A JP32185688A JPH02202A JP H02202 A JPH02202 A JP H02202A JP 63321856 A JP63321856 A JP 63321856A JP 32185688 A JP32185688 A JP 32185688A JP H02202 A JPH02202 A JP H02202A
- Authority
- JP
- Japan
- Prior art keywords
- active ingredient
- mixture
- pharmaceutical formulation
- sustained release
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000004480 active ingredient Substances 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 239000011248 coating agent Substances 0.000 claims abstract description 15
- 238000000576 coating method Methods 0.000 claims abstract description 15
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 12
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 12
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 12
- 238000013268 sustained release Methods 0.000 claims abstract description 11
- 239000012730 sustained-release form Substances 0.000 claims abstract description 11
- 238000004090 dissolution Methods 0.000 claims abstract description 10
- 239000011230 binding agent Substances 0.000 claims abstract description 5
- 239000003085 diluting agent Substances 0.000 claims abstract description 5
- 239000004014 plasticizer Substances 0.000 claims abstract description 4
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims abstract description 3
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960005316 diltiazem hydrochloride Drugs 0.000 claims abstract description 3
- 239000011859 microparticle Substances 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 6
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 229920003152 Eudragit® RS polymer Polymers 0.000 claims 2
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000008187 granular material Substances 0.000 abstract description 4
- 210000000936 intestine Anatomy 0.000 abstract description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract 4
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 210000004051 gastric juice Anatomy 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- 239000007921 spray Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- WWXUGNUFCNYMFK-UHFFFAOYSA-N Acetyl citrate Chemical compound CC(=O)OC(=O)CC(O)(C(O)=O)CC(O)=O WWXUGNUFCNYMFK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- -1 citric acid ester Chemical class 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 229940099371 diacetylated monoglycerides Drugs 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical group CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 241001123248 Arma Species 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- YFONKFDEZLYQDH-OPQQBVKSSA-N N-[(1R,2S)-2,6-dimethyindan-1-yl]-6-[(1R)-1-fluoroethyl]-1,3,5-triazine-2,4-diamine Chemical compound C[C@@H](F)C1=NC(N)=NC(N[C@H]2C3=CC(C)=CC=C3C[C@@H]2C)=N1 YFONKFDEZLYQDH-OPQQBVKSSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
- 229940031954 dibutyl sebacate Drugs 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000009408 flooring Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005395 methacrylic acid group Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005563 spheronization Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
め要約のデータは記録されません。
Description
方法に関するものである。
要である。何故なら、これらの投与剤形は活性成分を徐
々に体に放出し、活性成分を長期間にわたって体に供給
することを可能にし、更にこれらは、錠剤またはゼラチ
ン硬カプセルを繰り返して服用する困難さを患者からt
Jl°除するからである。
グされた微粒子のゼラチン硬カプセル剤は既に文献に記
載されている。
させ得る徐放性医薬投与剤形を目的とするものである。
形剤を含有しポリマーの混合物でコーティングされた微
粒子でも育成され、この微粒子をゼラチン硬カプセルに
入れたものである。
であり、エチルセルロースとエウドラジット(Iシud
ragiL)Rの混合物、より詳細には、60:40〜
40:60の割合のエチルセルロースとエウドラジット
R3の混合物である。
および結合剤からなる。
わけ80%を構成し得る。
えば、ポリビニルピロリドン、メチルヒドロキシプロピ
ルセルロース、および好ましくはカルボキシメチルセル
ロースである。
マーの混合物で構成され、溶媒または溶媒混液に入れて
微粒子に適用される。
の混合物は、エチルセルロース(40〜60ffiff
1%)ト−Cつ)’5 ジットR3(60〜40fl[
1%)の混合物である。
・フ1−マ(R6bm PI+arma) G11ll
)11 社製の、アクリル酸およびメタクリル酸のエス
テルのポリマー物質である。
衝化溶液に不溶であるが、これらの11に体中で膨潤し
、透過性になる。
5%のエウドラジットR3で構成されるのが好ましい。
、アセチル化モノグリセリド、プロピレングリコール、
ジブチルセバケート、グリセロールトリアセテート、ク
エン酸エステル、例丸ばクエン酸トリエチルエステル、
アセチルクエン酸トリエチルエステル、クエン酸トリブ
チルエステル、アセチルクエン酸トリブチルエステルま
たはアセチルクエン酸トリ(2−エチルヘキシル)エス
テルとすることができる。アセチル化モノグリセリドを
使用するのが好ましい。
さによって、活性成分の放出を異ならせることができる
。
または好ましくは、アセトン、酢酸エチル、塩化メチレ
ンおよびイソプロピルアルコールの様な有機溶媒である
。
:10の割合の混液の様な溶媒混液を使用することもで
きる。
溶媒混液中に含有させる。
ing)、回転造粒法(「oLary granul
aLion)、圧縮法(comPacLion)、押し
出し/球状化法(extrusion/5pheron
izaLion)のような種々の方法によって行うこと
ができる。後者の方法が好ましい方法である。
流動床(air−rluidized bed)()J
ラムを備えているか備えていない“トップ−スプレー”
または“ボトム−スプレー”噴1FI)または回転造粒
機(接触噴1′Fi)であってよいコーティング装置を
使用し、噴霧することによって行なう。
噴霧によって、空気流動床で行うのが好ましい。
りわけジルチアゼムを含有させることができる。
ース 19重量%カルボキシメチルセルロー
ス 1lllff1%M床 工fルセルo−スN22NF 41fflffE%エ
ウドラジットIts 50fflff1%
アセチル化モノグリセリド マイパセット(MyvacaL)9−40 9 ffl
ffi%65 : 35 アセトン/イソプロピルア
ルコール混液中6%強度のコーティング溶液を調製し、
剤皮が微粒子の乾燥重量の約4%になるまで噴霧する。
含有するコーティングされた微粒子で構成される。これ
らの条件下、ゼラチン硬カプセル剤には、90〜400
mgの活性成分を含有させることができる。
比較試験を行った。
ムのみを含有)の溶解は、p旧こ依存する。
pHに依存する。
はpHに依存する。
ウドラジッl−RS混合物でコーティングされた微粒子
の溶解は、ptlに依存しない。
ないという事実は非常に重要であり、活性成分の放出は
胃腸管全長にわたって媒質に関係なく均等に起こり得る
。
Claims (1)
- 【特許請求の範囲】 1、活性成分を含有し、エチルセルロースおよびエウド
ラジットRSの混合物でコーティングされた微粒子から
なる、pHに関係なく活性成分を制御溶解させ得る徐放
性医薬製剤。 2、コーティング用混合物が60〜40重量%のエチル
セルロースおよび40〜60重量%のエウドラジットR
Sからなる請求項1に記載の医薬製剤。 3、コーティング用混合物が45重量%のエチルセルロ
ースおよび55重量%のエウドラジットRSからなる請
求項1または2に記載の医薬製剤。 4、コーティング用混合物が更に可塑剤を含有する請求
項1〜3のいずれかに記載の医薬製剤。 5、コーティング用混合物がアセチル化モノグリセリド
を含有する請求項4に記載の医薬製剤。 6、微粒子が活性成分並びに希釈剤および結合剤を含有
する請求項1〜5のいずれかに記載の医薬製剤。 7、希釈剤が微結晶セルロースである請求項6に記載の
医薬製剤。 8、結合剤がカルボキシメチルセルロースである請求項
6または7に記載の医薬製剤。 9、活性成分がジルチアゼム塩酸塩である請求項1〜8
のいずれかに記載の医薬製剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8717855A FR2624732B1 (fr) | 1987-12-21 | 1987-12-21 | Formulation pharmaceutique a liberation prolongee |
FR8717855 | 1987-12-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH02202A true JPH02202A (ja) | 1990-01-05 |
JPH082782B2 JPH082782B2 (ja) | 1996-01-17 |
Family
ID=9358116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP63321856A Expired - Lifetime JPH082782B2 (ja) | 1987-12-21 | 1988-12-20 | 徐放性医薬製剤 |
Country Status (23)
Country | Link |
---|---|
US (1) | US5112621A (ja) |
EP (1) | EP0322277B1 (ja) |
JP (1) | JPH082782B2 (ja) |
KR (1) | KR960009650B1 (ja) |
AR (1) | AR243378A1 (ja) |
AT (1) | ATE71837T1 (ja) |
AU (1) | AU609916B2 (ja) |
CA (1) | CA1332567C (ja) |
DE (1) | DE3868037D1 (ja) |
DK (1) | DK172370B1 (ja) |
ES (1) | ES2051881T3 (ja) |
FI (1) | FI97445C (ja) |
FR (1) | FR2624732B1 (ja) |
GR (1) | GR3003826T3 (ja) |
HU (1) | HU199685B (ja) |
IE (1) | IE60313B1 (ja) |
IL (1) | IL88736A (ja) |
IT (1) | IT8723196A0 (ja) |
MX (1) | MX169322B (ja) |
NO (1) | NO179357C (ja) |
NZ (1) | NZ227412A (ja) |
PT (1) | PT89276B (ja) |
ZA (1) | ZA889495B (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06247844A (ja) * | 1993-02-25 | 1994-09-06 | Dai Ichi Seiyaku Co Ltd | カプセル製剤 |
JPH07507549A (ja) * | 1992-06-04 | 1995-08-24 | スミスクライン・ビーチャム・コーポレイション | 味の良い医薬組成物 |
KR100775957B1 (ko) * | 2006-02-07 | 2007-11-13 | 경상대학교산학협력단 | 애기장대 유래의 개화시기를 조절 단백질 co의 돌연변이단백질, 상기 단백질을 이용한 식물의 개화시기 조절전사인자의 분리방법 및 식물의 개화시기 조절방법 |
CN100442981C (zh) * | 2006-11-09 | 2008-12-17 | 广东省昆虫研究所 | 一种德国小蠊毒饵 |
KR101639163B1 (ko) * | 2015-07-08 | 2016-07-22 | 울산대학교 산학협력단 | 저전송 영상 정보 및 센싱 정보 송수신 장치 및 이의 동작 방법 |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03145418A (ja) * | 1989-10-27 | 1991-06-20 | Sumitomo Pharmaceut Co Ltd | 塩基性薬物塩酸塩の徐放性製剤 |
EP0452862B1 (en) * | 1990-04-18 | 1995-07-19 | Asahi Kasei Kogyo Kabushiki Kaisha | Spherical seed cores, spherical granules and process for production thereof |
US5286497A (en) * | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
ZA923474B (en) * | 1991-05-20 | 1993-01-27 | Marion Merrell Dow Inc | Diltiazem formulation |
US5288505A (en) * | 1991-06-26 | 1994-02-22 | Galephar P.R., Inc., Ltd. | Extended release form of diltiazem |
GB2258613B (en) * | 1991-08-12 | 1996-01-10 | Euro Celtique Sa | Pharmaceutical diltiazem formulation |
KR100221695B1 (ko) * | 1991-08-12 | 1999-09-15 | 그린 마틴, 브라이언 쥐 테슬리 | 약학적 구상 제형 |
US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5681585A (en) * | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US7070806B2 (en) * | 1992-01-27 | 2006-07-04 | Purdue Pharma Lp | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5260068A (en) * | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
US5837277A (en) * | 1992-06-04 | 1998-11-17 | Smithkline Beecham Corporation | Palatable pharmaceutical compositions |
US5376384A (en) * | 1992-12-23 | 1994-12-27 | Kinaform Technology, Inc. | Delayed, sustained-release pharmaceutical preparation |
US5834024A (en) | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
US5567441A (en) * | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
FR2742660B1 (fr) * | 1995-12-22 | 1998-04-03 | Ethypharm Lab Prod Ethiques | Nouvelles formes de microgranules a liberation prolongee contenant du diltiazem comme principe actif |
US6245351B1 (en) * | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
US5830503A (en) * | 1996-06-21 | 1998-11-03 | Andrx Pharmaceuticals, Inc. | Enteric coated diltiazem once-a-day formulation |
WO1999001111A1 (en) | 1997-07-02 | 1999-01-14 | Euro-Celtique, S.A. | Stabilized sustained release tramadol formulations |
KR100440553B1 (ko) * | 1998-03-26 | 2004-07-15 | 후지사와 야꾸힝 고교 가부시키가이샤 | 서방성 제제 |
US6524620B2 (en) | 1998-07-20 | 2003-02-25 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation and method of manufacture |
US5997905A (en) * | 1998-09-04 | 1999-12-07 | Mcneil-Ppc | Preparation of pharmaceutically active particles |
UA67802C2 (uk) | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
GB9825988D0 (en) * | 1998-11-27 | 1999-01-20 | Pfizer Ltd | Indole derivatives |
US20060153914A1 (en) * | 1999-12-10 | 2006-07-13 | Biovail Laboratories International S.R.L. | Chronotherapeutic diltiazem formulations and the administration thereof |
US7108866B1 (en) | 1999-12-10 | 2006-09-19 | Biovall Laboratories International Srl | Chronotherapeutic diltiazem formulations and the administration thereof |
US6635277B2 (en) | 2000-04-12 | 2003-10-21 | Wockhardt Limited | Composition for pulsatile delivery of diltiazem and process of manufacture |
GB0018968D0 (en) * | 2000-08-02 | 2000-09-20 | Pfizer Ltd | Particulate composition |
US6663896B1 (en) | 2001-08-01 | 2003-12-16 | Alvin S. Blum | Delayed release aspirin for vascular obstruction prophylaxis |
KR100407519B1 (ko) * | 2001-08-31 | 2003-12-18 | 부광약품 주식회사 | 건조황산제일철과 방출조절제로서 엘-글루타민을 함유하는서방성 정제 및 그의 제조방법 |
KR100446818B1 (ko) * | 2001-11-06 | 2004-09-01 | 김재윤 | 질산 이소소르비드 서방성 펠렛 제형 |
PE20050484A1 (es) | 2003-10-29 | 2005-10-13 | Wyeth Corp | Composicion farmaceutica de liberacion sostenida |
EP1730516A1 (en) * | 2004-03-30 | 2006-12-13 | Pfizer Products Incorporated | Method and device for evaluation of pharmaceutical compositions |
US20100062073A1 (en) * | 2006-11-29 | 2010-03-11 | Ronald Arthur Beyerinck | Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein |
US20100119612A1 (en) * | 2007-04-17 | 2010-05-13 | Bend Research, Inc | Nanoparticles comprising non-crystalline drug |
US20100080852A1 (en) * | 2007-05-03 | 2010-04-01 | Ronald Arthur Beyerinck | Phamaceutical composition comprising nanoparticles and casein |
WO2008135855A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer |
WO2008135828A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
US8974827B2 (en) * | 2007-06-04 | 2015-03-10 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
WO2008149230A2 (en) | 2007-06-04 | 2008-12-11 | Pfizer Products Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate |
US20100215747A1 (en) * | 2007-07-13 | 2010-08-26 | Corey Jay Bloom | Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers |
US9233078B2 (en) * | 2007-12-06 | 2016-01-12 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer |
EP2231169B1 (en) * | 2007-12-06 | 2016-05-04 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
EP2550863A1 (de) * | 2011-07-27 | 2013-01-30 | Bayer Intellectual Property GmbH | Aktivstoffhaltige Partikel auf Polyacrylat-Basis |
DK2970101T3 (en) | 2013-03-14 | 2018-08-20 | Alkermes Pharma Ireland Ltd | PRO-DRUGS OF FUMARATES AND THEIR USE IN TREATING DIFFERENT DISEASES |
CA2936748C (en) | 2014-10-31 | 2017-08-08 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU187215B (en) * | 1983-01-26 | 1985-11-28 | Egyt Gyogyszervegyeszeti Gyar | Method for producing pharmaceutical product of high actor content and prolonged effect |
US4533674A (en) * | 1983-10-24 | 1985-08-06 | Basf Wyandotte Corporation | Process for preparing a sugar and starch free spray-dried vitamin C powder containing 90 percent ascorbic acid |
SE457505B (sv) * | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning |
JPH0625055B2 (ja) * | 1985-03-18 | 1994-04-06 | 日本ケミフア株式会社 | 持続性錠剤 |
JPS625915A (ja) * | 1985-07-03 | 1987-01-12 | Nippon Iyakuhin Kogyo Kk | 塩酸ジルチアゼム徐放性製剤及びその製法 |
US4775536A (en) * | 1986-02-24 | 1988-10-04 | Bristol-Myers Company | Enteric coated tablet and process for making |
US4800087A (en) * | 1986-11-24 | 1989-01-24 | Mehta Atul M | Taste-masked pharmaceutical compositions |
-
1987
- 1987-12-21 FR FR8717855A patent/FR2624732B1/fr not_active Expired - Fee Related
- 1987-12-23 IT IT8723196A patent/IT8723196A0/it unknown
-
1988
- 1988-12-13 ES ES88403161T patent/ES2051881T3/es not_active Expired - Lifetime
- 1988-12-13 EP EP88403161A patent/EP0322277B1/fr not_active Expired - Lifetime
- 1988-12-13 AT AT88403161T patent/ATE71837T1/de not_active IP Right Cessation
- 1988-12-13 DE DE8888403161T patent/DE3868037D1/de not_active Expired - Lifetime
- 1988-12-20 HU HU886514A patent/HU199685B/hu unknown
- 1988-12-20 ZA ZA889495A patent/ZA889495B/xx unknown
- 1988-12-20 KR KR88017054A patent/KR960009650B1/ko not_active IP Right Cessation
- 1988-12-20 FI FI885884A patent/FI97445C/fi not_active IP Right Cessation
- 1988-12-20 IL IL88736A patent/IL88736A/xx unknown
- 1988-12-20 CA CA000586481A patent/CA1332567C/en not_active Expired - Lifetime
- 1988-12-20 JP JP63321856A patent/JPH082782B2/ja not_active Expired - Lifetime
- 1988-12-20 IE IE381088A patent/IE60313B1/en not_active IP Right Cessation
- 1988-12-20 DK DK708088A patent/DK172370B1/da not_active IP Right Cessation
- 1988-12-20 NZ NZ227412A patent/NZ227412A/xx unknown
- 1988-12-20 NO NO885641A patent/NO179357C/no unknown
- 1988-12-20 PT PT89276A patent/PT89276B/pt not_active IP Right Cessation
- 1988-12-20 MX MX014267A patent/MX169322B/es unknown
- 1988-12-20 AR AR88312796A patent/AR243378A1/es active
- 1988-12-20 AU AU27077/88A patent/AU609916B2/en not_active Expired
-
1990
- 1990-07-26 US US07/559,429 patent/US5112621A/en not_active Expired - Lifetime
-
1992
- 1992-02-18 GR GR920400248T patent/GR3003826T3/el unknown
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07507549A (ja) * | 1992-06-04 | 1995-08-24 | スミスクライン・ビーチャム・コーポレイション | 味の良い医薬組成物 |
JPH06247844A (ja) * | 1993-02-25 | 1994-09-06 | Dai Ichi Seiyaku Co Ltd | カプセル製剤 |
KR100775957B1 (ko) * | 2006-02-07 | 2007-11-13 | 경상대학교산학협력단 | 애기장대 유래의 개화시기를 조절 단백질 co의 돌연변이단백질, 상기 단백질을 이용한 식물의 개화시기 조절전사인자의 분리방법 및 식물의 개화시기 조절방법 |
CN100442981C (zh) * | 2006-11-09 | 2008-12-17 | 广东省昆虫研究所 | 一种德国小蠊毒饵 |
KR101639163B1 (ko) * | 2015-07-08 | 2016-07-22 | 울산대학교 산학협력단 | 저전송 영상 정보 및 센싱 정보 송수신 장치 및 이의 동작 방법 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH02202A (ja) | 徐放性医薬製剤 | |
JP3140764B2 (ja) | ミノサイクリンの脈動性1日1回放出系 | |
JP3015105B2 (ja) | 粉末被覆経口投与剤形 | |
US4927640A (en) | Controlled release beads having glass or silicon dioxide core | |
JP4107678B2 (ja) | 制御放出製剤 | |
US5246714A (en) | Drug preparation | |
US5824339A (en) | Effervescent composition and its production | |
KR950005864B1 (ko) | 서방성 제제 및 그의 제조방법 | |
DK175578B1 (da) | Farmaceutisk præparat med kontrolleret frigivelseshastighed | |
RU2235540C2 (ru) | Способ получения пероральной препаративной формы пролонгированного действия с регулируемым высвобождением активного вещества в зависимости от вида и количества наполнения желудка и пищеварительного тракта | |
PL188834B1 (pl) | Farmaceutyczne formulacje zawierające tramadol lub jego fizjologicznie akceptowane sole oraz sposóbwytwarzania tych formulacji | |
US8828426B2 (en) | Multiparticulate L-carnitine compositions and related methods | |
HU186538B (en) | Process for producing retarde pharmaceutical compositions containing bromohexine | |
HU214576B (hu) | Eljárás elnyújtott hatóanyag-leadású, többegységes, többrétegű bevonattal ellátott orális gyógyszerkészítmény előállítására | |
AU4735099A (en) | Preparation of pharmaceutically active particles | |
JPH04224517A (ja) | 標的制御釈放薬剤 | |
NZ517465A (en) | Controlled release pellet formulation | |
US5277916A (en) | Tetracycline dosage form | |
JPS5919526B2 (ja) | 制御された活性成分放出速度を有する調製物の製法 | |
WO2009002416A1 (en) | Controlled release tamsulosin hydrochloride formulation | |
WO2012170611A1 (en) | Multiparticulate 5-htp compositions and related methods | |
JP3645816B2 (ja) | ロラタジン及びプソイドエフェドリンを含有する医薬カプセル組成物 | |
US7604820B1 (en) | Solid preparation containing chitosan powder and process for producing the same | |
WO2009069089A9 (en) | Levetiracetam controlled release composition | |
CN1956707B (zh) | 包含n-(2-(2-苯二酰亚氨基乙氧基)-乙酰基)-l-丙氨酰基-d-谷氨酸(lk-423)的耐胃酸的药物剂型 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080117 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090117 Year of fee payment: 13 |
|
EXPY | Cancellation because of completion of term |